Skip to main content
. 2024 Jul 22;19:7415–7471. doi: 10.2147/IJN.S460047

Table 11.

Liposome Nanodelivery Systems for Cancer Therapy

Type of Nanosystems Loaded Drugs Diameter (nm) Zeta Potential (mV) PDI Functional Modifications Aimed Cells Aimed Tumor Animal Models Ref
Hypoxia-sensitive liposome Vinblastine-N-oxide (CPD100) 142±4.16 155.4 ± 4.2 0.11±0.005 A23187 ES2 cells Ovarian cancer Female Swiss Webster mice [323]
Hypoxia-sensitive liposome DOX 181 ± 3 −34.4 ± 1.3 0.34 ± 0.07 Nitroimidazole derivative, RM-1, FaDu cells Hypoxic tumor Cell line and patient-derived xenograft [324]
Liposome DOX 92.2±0.4 −16.3 0.21±0.01 Albumin-binding domain (ABD) 4T1 Breast cancer Mice bearing 4 T1 tumors [332]
PH-sensitive liposome HCQ, DOX 121.89±1.59 pH 7.4, −4.36 ± 0.16, pH 6.5, 12.12 ± 0.08 TH peptide, RGD B16F10, MCF-7 B16F10 xenograft-bearing mice [325]
GSH- sensitive liposome DOX 65.2 ± 5.7 –14.6 ± 3.3 GSH BxPC3, Huh7 HCC\ poorly permeable pancreatic tumors Mice bearing subcutaneous BxPC3 tumors [333]
MMP sensitive liposome (Cleavable) DOX 140 −17.6 ± 0.6 0.059 ± 0.025 PEG PC3 cells PC3 cells derived xenograft [334]
Liposome DOX Nanobowl 4T1 Breast tumor Orthotopic 4T1 breast tumor mouse model [335]
Dual-layered Au-liposome 72.84±22.49 −17.7 64Cu\PEG 4T1 Orthotopic 4T1 breast tumor mouse model [336]
Targeting liposome PTX 112.5±4.1 −34.4±0.8 0.25±0.009 Ginsenosides BGC-823 Gastric cancer BGC-823 cells derived xenograft [337]
Thermosensitive magnetic liposomes Irinotecan, Fe3O4 193.7 ± 2.3 2.3 ± 0.1 0.22 0.01 CET U87 cell Brain tumor U87 cells derived xenograft [338]
PET imaging liposomes 129.0 ± 2.2 −16.53 ± 1.3 Glucose- and DOTA-Cu2+ A431 A431 derived xenograft [339]
Targeting liposome DTX 96.7±4.5 Ginsenoside Rg3 4T1 TNBC Orthotopic TNBC model [340]
Liposome Clodronate 101.8±24.4 − 21 ± 5.04 0.2 4T1 cells 4T1 breast cancer-bearing mice [341]
Liposomes with targeted Photochlor (HPPH)\ evofosfamide 128.7 ± 75.0 29.97 ± 3.5 Chitosan oligosaccharide MDA-MB-231 TNBC MDA-MB-231 tumor model [342]
Dual-Targeting liposome Cabozantinib\ IDO 115.53±2.35 0.14±0.01 115.53±2.35 4T1 TNBC TNBC xenograft-bearing mice [343]
Liposome DOX 200 Holo-Lf 4T1 4T1 xenograft-bearing mice [344]
Liposome ASOs 150 ± 36 −6.67 ± 0.18 0.0838 Tumor-penetrating peptide, iRGD 22Rv1, LNCaP, and VCaP Bone metastasis model, 4T1 orthotopic tumor model [345]
Liposome DMC 40 Pyrophaeophorbid CT26 Mice bearing CT26 tumor Colorectal cancer [346]
PH-sensitive liposome UA 135.4 ± 0.636 7.8 0.3 Chitosan U14cell [326]
Targeting liposome HAPO-1048, IR-1048 135.2 –32.97±2.36 HA UM-UC-3 Bladder cancer Orthotopic BC model [347]
Targeting liposome Honokiol 162.6 ± 3.8 −38.24 0.26 ± 0.02 HA 4T1 cells Breast cancer 4T1 tumor-bearing mouse model [348]

Abbreviations: HCQ, hydroxychloroquine; GSH, glutathione; CET, Cetuximab; DTX, docetaxel; TNBC, triple-negative breast cancer; IDO, Indoleamine 2,3-dioxygenase; Holo-Lf, holo-lactoferrin; ASOs, antisense oligonucleotides; HCC, hepatocellular carcinoma; ASOs, antisense oligonucleotides; DMC, demethylcantharidin; UA, ursolic acid.